Growth factors and the management of the diabetic foot

Diabetic Medicine, Supplement

Volumn 22, Issue 1, 2005, Pages 12-14

  Amery, C M ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BECAPLERMIN; CT 102; EPIDERMAL GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 1BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR BB; TRANSFORMING GROWTH FACTOR BETA2;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC FOOT; DRUG COST; DRUG EFFICACY; HUMAN; REVIEW; RISK FACTOR; SIDE EFFECT; ULCER HEALING; WOUND HEALING IMPAIRMENT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESEARCH; FOOT CARE; WOUND HEALING;

EID: 13244258387     PISSN: 14665468     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.1531f.x     Document Type: Review

References (10)

1. Consensus Development Conference on Diabetic Foot Wound Care. Diabetes Care 1999; 22: 1354-1360.
2. Smiell JM, Wieman TJ, Steed DL, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomised studies. Wound Repair Regeneration 1999; 7: 335-346.
3. Falanga V. New Treatments for Diabetic Foot Ulcers(a) Growth Factors. In: The Foot in Diabetes, 3rd edn. Chichester: John Wiley & Sons, 2000; 14: 171.
4. Hehenberger K, Kratz G, Hansson A, Brismar K. Fibroblasts derived from human chronic diabetic wounds have a decreased proliferation rate, which is recovered by the addition of heparin. J Dermatol Sci 1998; 16: 144-151.
5. Blakytny R, Jude EB, Gibson MJ, Boulton AJ, Ferguson MW. Lack of insulin-like growth factor (IGF1) in the basal keratinocytes layer of diabetic skin and diabetic foot ulcers. J Pathol 2000; 190: 589-594.
6. Jude EB, Blakytny R, Bulmer J, Boulton AJ, Ferguson MWJ. Transforming growth factor-beta 1,2,3 and receptor type I and II in diabetic foot ulcers. Diabet Med 2002; 19: 440-447.
7. Eldor R, Raz I, Ben Yehuda A, Boulten AJM. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med 2004; 21: 1161-1173.
8. Monthly Index of Medical Specialities. Haymarket Medical Publications Ltd, May 2004; 298.
9. Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy/Wound Manage 2003; 49: 76-84.
10. Perry BH, Sampson AR, Schwab BH, Rezaul KM, Smiell JM. A meta-analytic approach to an integrated summary of efficacy: a case study of becaplermin gel. Controlled Clin Trials 2002; 23: 389-408.